Abstract
The purpose of this study was to clarify the effects of a 1-year treatment with either alendronate or risedronate on the proximal femoral geometry among Japanese women with osteoporosis by hip structure analysis. Postmenopausal women who had taken at least 90% of their prescription for alendronate (35 mg/week, 94 patients) or risedronate (17.5 mg/week, 181 patients) for 1 year were retrospectively analyzed. In the alendronate treatment group, bone mineral density (BMD), cross-sectional area (CSA), section modulus and average cortex significantly increased by 0.81, 1.35, 2.23 and 0.97% at the narrow neck and increased by 2.19, 2.28, 2.85 and 1.11% at the intertrochanteric, respectively. Buckling ratio at the intertrochanteric significantly decreased by 2.50%. The CSA, section modulus and average cortex at the shaft significantly increased at 1 year. In the risedronate treatment group, the CSA, section modulus and average cortex at the narrow neck significantly increased by 0.80, 0.95 and 0.89%, respectively. BMD, CSA, section modulus, and average cortex at the intertrochanteric significantly increased by 1.61, 0.88, 2.05 and 0.79%, respectively, and buckling ratio significantly decreased by 1.53%. BMD, CSA, section modulus, and average cortex at the shaft significantly increased. The percent change of section modulus was significantly correlated with that of BMD, CSA and average cortex and negatively correlated with that of buckling ratio at all regions in both treatment groups. Statistically significant differences between the alendronate and risedronate groups were seen for section modulus in the narrow neck and CSA in the intertrochanteric. In conclusion, Japanese osteoporotic women treated by either alendronate or risedronate showed significant improvements of geometry in proximal femur within 1 year.
Similar content being viewed by others
References
Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936
Miller PD (2003) Bone mass measurements. Clin Geriatr Med 19:281–297
Schott AM, Cormier C, Hans D, Favier F, Hausherr E, Dargent-Molina P, Delmas PD, Ribot C, Sebert JL, Breart G, Meunier PJ, for EPIDOS Group (1998) How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 8:247–254
Li Z, Meredith MP, Hoseyni MS (2001) A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 20:3175–3188
Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Dennis M, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289
Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1–10
Beck TJ, Ruff CB, Warden KE, Scott WW Jr, Rao GU (1990) Predicting femoral neck strength from bone mineral data: a structural approach. Invest Rad 25:6–18
Beck TJ, Ruff CB, Scott WW Jr, Plato CC, Tobin JD, Quan CA (1992) Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif Tissue Int 50:24–29
Beck TJ, Ruff CB, Bissessur K (1993) Age-related changes in female femoral neck geometry: implications for bone strength. Calcif Tissue Int 53(Suppl 1):S41–S46
Beck TJ, Looker AC, Ruff CB (2000) Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res 15:2297–2304
Wang XF, Duan Y, Beck TJ, Seeman E (2005) Varying contributions of growth and ageing to racial and sex differences in femoral neck structure and strength in old age. Bone 36:978–986
Uusi-Rasi K, Beck TJ, Semanick LM, Daphtary MM, Crans GG, Desaiah D, Harper KD (2006) Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos Int 17:575–586
Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA (2005) Effect of hormone replacement, alendronate, or combination therapy on hip structure geometry: a 3-year, double blind, placebo-controlled clinical trial. J Bone Miner Res 20:1525–1532
Uusi-Rasi K, Semanick LM, Zanchetta JR, Bogado CE, Eriksen EF, Sato M, Beck TJ (2005) Effects of teriparatide [rh PTH (1–34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 36:948–958
Bonnick SL, Beck TJ, Cosman F, Hochberg MC, Wang H, de Papp AE (2009) DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass. Osteoporos Int 20:911–921
Beck TJ, Lewiecki EM, Miller PD, Felsenberg D, Liu Y, Ding B, Libanati C (2008) Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate. J Clin Densitom 11:351–359
Takada J, Beck TJ, Iba K, Yamashita T (2007) Structural trends in the aging proximal femur in Japanese postmenopausal women. Bone 41:97–102
Takada J, Miki T, Imanishi Y, Nakatsuka K, Wada H, Naka H, Yoshizaki T, Iba K, Beck TJ, Yamashita T (2010) Effects of raloxifene treatment on structural geometry of the proximal femur in Japanese women with osteoporosis. J Bone Miner Metab 28:561–567
Ito M, Sone T, Fukunaga M (2010) Effect of minodronic acid hydrate on hip geometry in Japanese women with postmenopausal osteoporosis. J Bone Miner Metab 28:334–341
Uchida S, Taniguchi T, Shimizu T, Kakikawa T, Okuyama K, Okaniwa M, Arizono H, Nagata K, Santora AC, Shiraki M, Fukunaga M, Tomomitsu T, Ohashi Y, Nakamura T (2005) Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab 23:382–388
Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, for the Risedronate Phase III Research Group (2006) Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 24:405–413
Osteoporosis diagnostic criteria review committee: Japanese society for bone, mineral research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337
Hans D, Duboeuf F, Schott AM, Horn S, Avioli LV, Drezner MK, Meunier PJ (1997) Effects of a new positioner on the precision of hip bone mineral density measurements. J Bone Miner Res 12:1289–1294
Ruff CB, Hayes WC (1983) Cross-sectional geometry of Pecos Pueblo femora and tibiae––a biomechanical investigation. I. Method and general patterns of variation. Am J Phys Anthropol 60:359–381
Melton LJ III, Beck TJ, Amin S, Khosla S, Achenbach SJ, Oberg AL, Riggs BL (2005) Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int 16:460–467
Nelson DA, Barondess DA, Hendrix SL, Beck TJ (2000) Cross-sectional geometry, bone strength, and bone mass in the proximal femur in black and white postmenopausal women. J Bone Miner Res 15:1992–1997
Acknowledgments
The authors wish to acknowledge Dr. Thomas J. Beck for his assistance.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Takada, J., Katahira, G., Iba, K. et al. Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis. J Bone Miner Metab 29, 458–465 (2011). https://doi.org/10.1007/s00774-010-0242-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-010-0242-8